Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-HER2 antibodies and compositions

An antibody composition and composition technology, applied in the direction of antibodies, drug combinations, antibody medical components, etc., can solve problems such as large room for improvement

Inactive Publication Date: 2013-01-16
SYMPHOGEN AS
View PDF12 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, while monoclonal antibodies targeting HER2 may improve therapeutic efficacy, for example in the treatment of HER2-overexpressing metastatic breast cancer, there is still much room for improvement

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-HER2 antibodies and compositions
  • Anti-HER2 antibodies and compositions
  • Anti-HER2 antibodies and compositions

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0633] Example 1: Cloning of Anti-HER2 Antibody

[0634] immunity

[0635] Female BALB / c (strain A) or C57B16 mice (8-10 weeks old) were immunized by injecting purified different proteins and HER2 overexpressing cells.

[0636] Commercially available HER2 protein (R&D Systems cat. #1129-ER) was used for immunization. Human breast cancer cell line AU565 (ATCC, CRL-2351) was used for cellular immunization. Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin (P / S). Before each immunization, cells were washed with PBS, digested with TrypLE, and resuspended in growth medium. The cell suspension was then washed twice with PBS, centrifuged at 250 g for 5 minutes, then removed and resuspended in 15 ml sterile PBS.

[0637] Cells or antigen were diluted in PBS and mixed 1:1 with Freund's adjuvant. Freund's adjuvant enhances and modulates the immune response. For the first immunization, complete Freund's adjuvan...

example 2

[0672] Example 2: Functional characterization of selected anti-HER2 antibodies

[0673] Using a viability assay, 41 unique antibodies were selected for functional testing. Cell damage inevitably leads to the cell's ability to maintain and provide energy for metabolic cell function and growth. Metabolic activity assays based on this premise typically measure mitochondrial activity. Cell Proliferation Reagent WST-1 (Roche Cat. No. 11 644 807 001) is a ready-to-use substrate for measuring metabolic activity in living cells. It is hypothesized that metabolic activity correlates with the number of viable cells. In this example, the WST-1 assay was used to measure the number of metabolically active cells treated with 2 μg / ml of different anti-HER2 antibodies for 96 hours.

[0674] The cancer cell lines SKBR-3 (ATCC cat.#HTB-30), BT-474 (ATCC cat.#HTB-20), NCI-N87 (ATCC cat.#CRL-5822) and MDA-453 (ATCC cat. #HTB-130) was inoculated into a 96-well plate at a concentration of 1000 ...

example 3

[0680] Example 3: Determining overlapping epitopes

[0681] In order to select compounds containing anti-HER2 antibodies that exert a synergistic effect in combination, the antibodies in each mixture should bind to non-overlapping epitopes. Therefore, in order to investigate the degree of overlap among anti-HER2 antibodies, epitope pooling was performed using surface plasmon resonance (SPR) technology. Available at ProteOn TM SPR analysis was performed with the XPR 36 protein interaction array system (Biorad Laboratories). The system can measure 6 interactions in two directions (defined as L and A), simultaneously generating a total of 36 possible interactions.

[0682] set up

[0683] ProteOn GLC sensor chips (BioRad) were conjugated to anti-Fc antibodies (Biacore, GE Healthcare) at 3600-3620 resonance units (RU) that could be injected into flow cells L1 to L6 using the ProteOn Amino Conjugation Kit according to the manufacturer's instructions (Biorad). Using a flow rat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions, and use of the antibodies and antibody composition for treatment of cancers. The antibody composition comprises at least three recombinant antibodies that bind distinct epitopes of HER2. Two of the antibodies bind to HER2 on the surface of a cell such that they generate a cross-linked antibody-receptor lattice on the cell surface and thereby result in HER2 receptor internalization. The third antibody in the composition binds HER2 such that it blocks heterodimerization between HER2 and HER3.

Description

field of invention [0001] The present invention relates to novel HER2 receptor targeting recombinant antibodies and compositions thereof (comprising 2 or more such antibodies) for use in the treatment of human cancers. Background of the invention [0002] The epidermal growth factor (EGFR) family (ie ErbB family) is a subfamily of tyrosine kinase (RTK) receptors, which includes 4 members: EGFR / ErbB, HER2 / ErbB2, HER3 / ErbB3 and HER4 / ErbB4. EGFR family members are closely related to single-chain regulatory glycoproteins with an extracellular ligand-binding domain, a single transmembrane domain, and intracellular kinases (see review Ferguson (2008) Annu Rev Biophys. 37:353-373). Under normal physiological conditions, the ErbB family regulates and coordinates important events in cell growth, proliferation and migration (Citri et al. (2006) Nat Rev Mol Cell Biol. 7:505-516). EGFR, HER2 and HER3 are now believed to play key roles in the malignant transformation of normal cells and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/30A61K39/00
CPCC07K2317/77C07K16/32C07K2317/30C07K2317/734A61K2039/507C07K2317/732C07K2317/76C07K2317/73A61P35/00
Inventor M·W·佩德森A·詹森P-J·梅杰
Owner SYMPHOGEN AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com